Ethical use of off-label disease-modifying therapies for multiple sclerosis.
Joanna Laurson-DoubeNick RijkeAnne HelmePeer BanekeBrenda BanwellViswanathan ShanthiBernhard HemmerBassem YamoutPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
The principles and process are endorsed by the World Federation of Neurology (WFN), American Academy of Neurology (AAN), European Academy of Neurology (EAN), Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Middle-East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) and Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), and we have regularly consulted with the Brain Health Unit, Mental Health and Substance Use Department at the World Health Organization (WHO).